logo
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

Yahoo15-05-2025

- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS'' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient has been dosed in the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
'Building upon our promising Cohort 3 data, we are pleased to dose our first pediatric AML patient as part of the ongoing Phase 2 trial,' said Dragan Cicic, MD, Chief Development Officer of SELLAS. 'This milestone reflects our commitment to addressing critical unmet needs in hematologic disorders as we develop treatments for the most difficult to treat patients, particularly pediatric patients, with very few available options, including multi-hit TP53 mutation, failure of azacitidine and venetoclax, failure of transplant, and almost all available high-intensity chemotherapies. With the Rare Pediatric Disease Designation already in place, we are hopeful that our work will bring meaningful progress and potential regulatory advantages as we continue to advance this important program.'
SELLAS was granted the FDA RPDD for the treatment of pediatric AML in July 2024. If, in the future, a New Drug Application (NDA) for SLS009 for the treatment of pediatric AML is approved by the FDA, SELLAS will be eligible to receive a Priority Review Voucher (PRV) that could be redeemed to receive a priority review for any subsequent marketing application. PRVs may be used by the sponsor or sold to another sponsor for their use and have recently sold for approximately $100 million.
The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg. In the 60 mg dose cohort, patients were treated at either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include two additional cohorts, one with ASXL1-mutated AML patients and one with patients with myelodysplasia-related molecular abnormalities other than ASXL1. The target response rate at the optimal dose level is 20% with a target median survival of at least 3 months. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrials.gov identifier NCT04588922.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BBAI Deadline Today: Rosen Law Firm Urges BigBear.ai Holdings, Inc. (NYSE: BBAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
BBAI Deadline Today: Rosen Law Firm Urges BigBear.ai Holdings, Inc. (NYSE: BBAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Business Wire

time16 minutes ago

  • Business Wire

BBAI Deadline Today: Rosen Law Firm Urges BigBear.ai Holdings, Inc. (NYSE: BBAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the 'Class Period'). is an artificial intelligence ('AI')-driven technology solutions company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Holdings, Inc. (NYSE: BBAI) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (2) as a result, incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under Accounting Standards Codification ('ASC') 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (3) accordingly, had improperly accounted for the 2026 Convertible Notes; (4) the foregoing error caused to misstate various items in several of previously issued financial statements; (5) as a result, these financial statements were inaccurate and would likely need to be restated; (6) would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that would be unable to timely file certain financial reports with the SEC; and (7) as a result, public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 10, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.

Intero Real Estate Professionals Named in 2025 RealTrends Verified Rankings
Intero Real Estate Professionals Named in 2025 RealTrends Verified Rankings

Yahoo

time21 minutes ago

  • Yahoo

Intero Real Estate Professionals Named in 2025 RealTrends Verified Rankings

223 Agents and Teams Were Honored on the Prestigious RealTrends Verified and The Thousand CUPERTINO, Calif., June 10, 2025--(BUSINESS WIRE)--Intero, a wholly owned subsidiary of HomeServices of America, Inc., is pleased to announce recognition of 186 individual agents and 37 teams who made the 2025 RealTrends Verified rankings. "Our agents and teams are named to the RealTrends Verified and The Thousand lists each year and the number of honorees from Intero increased this year," said Terry Meyer, Co-Founder and President of Intero. "We are so proud of their accomplishments, and the dedication they give to their clients." The annual reports are a state-by-state ranking of the top 1.5% of real estate professionals in the country (RealTrends Verified, the only agent and team ranking survey that requires verification) and a summary of the top 1,000 independent real estate agents and teams in the United States (RealTrends Verified + Tom Ferry The Thousand). For The Thousand, the Tse Group (#2) and the Troyer Group (#14) made the top 250 by Sales Volume for Large Teams, while Eric Fischer-Colbrie (#207) was also honored in the top 250 by Sales Volume for Individual Agents. "We have an amazing opportunity to work with some of the smartest, best-trained professionals in the real estate business," said Scott Chase, President of Intero, "and these rankings continue to highlight that our culture of collaboration and mentorship really works." RealTrends Verified Real Estate Professionals includes those named in The Thousand plus the next level of top producers. Top-producing agents must have closed at least 25 transaction sides or $10M in closed sales volume and teams must have closed 40 transaction sides or $16M in closed sales volume in 2024. The complete lists of RealTrends Verified and The Thousand can be found on RealTrends Verified's website, About Intero Intero, a wholly owned subsidiary of HomeServices of America Inc., serves Northern California and Nevada with 16 offices throughout the greater Silicon Valley, San Francisco, Western Nevada, and the Greater Lake Tahoe Region. The Intero Franchise network comprises 25 affiliates located in California, Nevada, Tennessee, and Texas. The company is headquartered in the heart of California's Silicon Valley. Find more information about Intero at Find more information about HomeServices of America at View source version on Contacts Derek Overbey – Intero Real Estate Servicesdoverbey@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lytx Launches Surfsight AI-14 Dash Cam, Setting a New Standard for Commercial Fleet Safety and Efficiency
Lytx Launches Surfsight AI-14 Dash Cam, Setting a New Standard for Commercial Fleet Safety and Efficiency

Yahoo

time26 minutes ago

  • Yahoo

Lytx Launches Surfsight AI-14 Dash Cam, Setting a New Standard for Commercial Fleet Safety and Efficiency

Surfsight AI-14, Leveraging Lytx's Industry-Leading MV+AI Technology, Provides Enterprise-Grade Reliability, Empowering Fleets to Elevate Safety, Reduce Liability, and Attain Best-in-Class Performance SAN DIEGO, June 10, 2025 /PRNewswire/ -- Lytx® Inc., the industry pioneer of video and safety-driven efficiency, today announced the launch of the Lytx Surfsight™ AI-14 dash cam powered by Lytx's advanced technology. Featuring the next generation of Lytx's machine vision and artificial intelligence (MV+AI) technology, the AI-14 dash cam offers greater risk detection, durability, intelligence, global coverage, and versatile privacy controls to meet the evolving needs of fleets and ecosystem partners across the globe. The AI-14 is built on the culmination of decades of Lytx's video safety expertise and innovation. Designed to preserve the sleek and compact hardware dimensions of its predecessor, which just reached its 300,000 active devices milestone, the new AI-14's functional enhancements elevate what fleets can expect from dash cam technology. As the global demand for smarter, safer, and more efficient fleet solutions accelerates, the AI-14 emerges not just to meet today's challenges, but to deliver future innovations. Offering beneficial insights, real-time risk detection, and the power to elevate fleet safety and efficiency like never before, the enterprise-grade Surfsight AI-14 dash cam is built to last, designed to inform, and ready for the world. The AI-14 announcement video can be viewed here. For additional visuals and details, please visit the official product page. "Centered on improving fleet and driver safety, the AI-14 was developed for evolving reseller partner and fleet needs and delivers a flexible, open platform, powerful hardware, configurability, and enables fast time to market," said Casey McGee, Chief Revenue Officer at Lytx. "With these enterprise-ready devices being deployed now, our reseller partners and fleets worldwide are better equipped to meet the unique challenges of the road and their daily operations." Powered with the AI-14 dash cam, Lytx Surfsight delivers: Proactive Risk Detection: On-board award-winning MV+AI technology to proactively identify and detect driving risk at the edge. Real-Time Driver Alerts: Visual and audio in-cab alerts help keep drivers attentive and focused, promoting safer road habits. Integrated Touchscreen: The only dash cam in its class with an LCD touchscreen, making installation, configuration, and operation intuitive and efficient. Configurable Audio Recording: Flexible audio recording options can enable the capture of sound inside and outside the vehicle. Road-Facing ADAS Features: Includes following distance, critical distance, and rolling stop. Pedestrian detection and red light detection will be added soon. Passenger Limit: Notifies fleets when cabin occupancy exceeds the defined threshold and captures valuable data to support investigations, enforce policy, and recover assets. Tamper-Resistant Design: Built to deter unauthorized removal, vandalism, and theft for added security and reliability. Event Tagging Made Easy: Convenient record buttons let drivers mark key events, simplifying video review and retrieval. Seamless Updates: Over-the-air firmware updates ensure the device stays current, eliminating the need for manual downloads. "Surfsight AI-14 elevates and enhances what our reseller partners and fleets already love about the Surfsight platform, such as the lens as a sensor setting, which captures risk without recording, and streaming recorded video on demand," said Rajesh Rudraradhya, Chief Technology Officer at Lytx. "Our innovation helps protect a world in motion and we're driven by fleets who prioritize telematics and want to add video, while also keeping safety top of mind. The AI-14 will continue to support those endeavors with fatigue detection and as new front-facing ADAS features like pedestrian and red light detection are added." "The launch of the Lytx Surfsight AI-14 is an exciting development, and we extend our congratulations to the Lytx team," said Robin Kinsey, AVP Geotab Marketplace. "This advanced camera reflects Lytx's dedication to innovation in video telematics and for a safer future, a vision we deeply share at Geotab." Lytx Surfsight AI-14 is available now in North America and will be released in other regions in the coming months (release dates vary by region). For Geotab customers, it will be available through their Order Now program starting in September 2025. About LytxLytx is a global leader in video safety and video telematics. Our solutions harness the power of video to empower drivers and fleets to be safer and more efficient, productive, and profitable so they can thrive in today's competitive environment. Through the Lytx Vision™ Platform, direct and reseller clients access our customizable services and programs spanning fleet safety, risk detection, fleet tracking, ELD compliance, preventative maintenance, and fuel management. Using the world's largest driving database of its kind, along with proprietary machine vision and artificial intelligence technology, we help protect and connect thousands of fleets and over 5.5 million drivers in more than 90 countries. For more information about Lytx, visit @lytx on X, LinkedIn, our Facebook page, or our YouTube channel. Contact:Jason Andersenpress@ View original content to download multimedia: SOURCE Lytx, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store